Why Psychiatry Can’t Ignore Metabolic Health Anymore
Metabolic psychiatry has moved past being a fringe theory. It is a practical, evidence-based necessity for a field that has been stagnant for too long.
Can Precision Psychiatry Be Delivered Remotely? The Limits and Opportunities of Telehealth in Interventional Care
How much of precision interventional psychiatry can actually happen remotely, and where does the model hit a wall? The answer is potentially more nuanced than the conventional framing suggests.
Where Will AI Deployment Benefit Payers the Most?
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
Behind “Rise of Malingering” in ER Psychiatry: Why Better Patient Classification Matters
Malingering, deliberately feigning or exaggerating symptoms appears to be rising. This shift brings with it a tangled web of clinical, operational, and ethical challenges that affect not only providers but also the patients most in need of timely, effective care.
The Keys to Better Mental Healthcare in 2025? Precision, Personalization, and Progress
We now have the ability to diagnose and treat with data-driven insights and deliver measurable outcomes. It’s on us as providers to ensure that we are consistently adopting the latest, proven technology and treatment modalities that can benefit our patients.
Precision Psychiatry is Possible — Especially if We Use Evidence-based Neural Measures to Drive Better Mental Health Treatment and Outcomes
By moving beyond subjective and heterogeneous criteria and embracing objective brain function measures, the field of psychiatry can achieve greater precision and efficacy in addressing complex disorders.
BetterHelp, Talkiatry Collaborate To Offer Psychiatric Services to Employers
Through a new partnership, employees of BetterHelp’s employer clients can access Talkiatry’s psychiatry services on an in-network basis at no extra cost.
presented by
Closing the Quality-Affordability Gap in Workplace Mental Health
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
MA Beneficiaries Have Fewer In-Network Options for Psychiatrists Than Other Insurance Types
A Health Affairs study discovered that nearly two-thirds of Medicare Advantage psychiatrist networks, or 64.6%, were narrow in 2019. Comparatively, about 43.1% of Medicaid managed care networks were narrow and 39.5% of ACA Marketplaces were narrow.
Horizon Healthcare Services Taps Talkiatry for Virtual Psychiatric Care
Talkiatry is now available to Horizon Healthcare Services’ commercial members at no additional cost, giving 3.6 million people access to the virtual mental health services. The company treats patients ages 5 years and older for conditions including anxiety, depression and bipolar disorder.
A new California law aims to strengthen access to mental health services
A California law signed Oct. 8 by Gov. Gavin Newsom requires that mental health and substance abuse patients be offered return appointments no more than 10 days after a previous session, unless their provider OKs less frequent visits.
Aetna, Inpathy expand virtual mental health partnership
Access to mental healthcare continues to be a hurdle amid the Covid-19 pandemic, prompting Aetna and telehealth provider Inpathy to expand their existing mental health partnership to include three more states.
presented by
The Healthcare Payments Industry Faces a Perception Challenge
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
Intra-Cellular share price drops after FDA cancels expert panel meeting for schizophrenia drug
The company said the decision to cancel the advisory committee meeting for lumateperone was made so the agency would have additional time to review information the firm had provided regarding the drug.
Acadia Pharmaceuticals drug flops in Phase III schizophrenia study
Nuplazid, which is FDA-approved for Parkinson's psychosis, failed to fully improve symptoms as an adjunctive treatment for schizophrenia.
Intra-Cellular Therapies hits one, misses another in Phase III bipolar disorder program
The company's shares fell more than 20 percent Monday on data from the trials of lumateperone, but an analyst wrote that the reason for the high placebo response rate that led to one trial's failure remains unclear.
Online therapy company Talkspace raises $50M, signs major deal with Optum
Interest and investment in the online therapy space has been ramping up as the technology has been positioned as a lever to address the larger issue of expanding access to behavioral health resources.
Clinical trials of Allergan’s antidepressant rapastinel fail
An analyst said the news could negatively affect shares of a successor to the company that developed rapastinel - which Allergan bought in 2015 - given that its drugs belong to the same class.